Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1–CH3 fusion protein-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1–CH3 fusion protein

Published:2018-08-04 Issue:10 Volume:67 Page:1621-1634
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Pan Zeyan,Di Shengmeng,Shi Bizhi,Jiang Hua,Shi Zhimin,Liu Ying,Wang Yi,Luo Hong,Yu Min,Wu Xiuqi,Li Zonghai

Funder

Shanghai Science and Technology Innovation Action Plan

Collaborative Innovation Center for Translational Medicine at Shanghai Jiao Tong University School of Medicine

Research Fund of Shanghai Municipal Commission of Health and Family Planning

the National Natural Science Foundation of China

the “13th Five-Year Plan” National Science and Technology Major Project of China

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/article/10.1007/s00262-018-2221-1/fulltext.html

Reference48 articles.

1. Lim WA, June CH (2017) The principles of engineering immune cells to treat cancer. Cell 168(4):724–740. https://doi.org/10.1016/j.cell.2017.01.016

2. Gao H, Li K, Tu H, Pan X, Jiang H, Shi B, Kong J, Wang H, Yang S, Gu J, Li Z (2014) Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer Res 20(24):6418–6428. https://doi.org/10.1158/1078-0432.CCR-14-1170

3. Zhai B, Shi D, Gao H, Qi X, Jiang H, Zhang Y, Chi J, Ruan H, Wang H, Ru QC, Li Z (2017) A phase I study of anti-GPC3 chimeric antigen receptor modified T cells (GPC3 CAR-T) in Chinese patients with refractory or relapsed GPC3 + hepatocellular carcinoma (r/r GPC3 + HCC). J Clin Oncol 35(suppl; abstr):3049

4. Katz SC, Burga RA, McCormack E, Wang LJ, Mooring W, Point GR, Khare PD, Thorn M, Ma Q, Stainken BF, Assanah EO, Davies R, Espat NJ, Junghans RP (2015) Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA + liver metastases. Clin Cancer Res 21(14):3149–3159. https://doi.org/10.1158/1078-0432.CCR-14-1421

5. Zhang C, Wang Z, Yang Z, Wang M, Li S, Li Y, Zhang R, Xiong Z, Wei Z, Shen J, Luo Y, Zhang Q, Liu L, Qin H, Liu W, Wu F, Chen W, Pan F, Zhang X, Bie P, Liang H, Pecher G, Qian C (2017) Phase I escalating-dose trial of CAR-T therapy targeting CEA + metastatic colorectal cancers. Mol Ther 25(5):1248–1258. https://doi.org/10.1016/j.ymthe.2017.03.010

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring Glypican-3 as a Molecular Target in Hepatocellular Carcinoma: Perspectives on Diagnosis and Precision Immunotherapy Strategies;Frontiers in Bioscience-Landmark;2024-07-24

2. The role of PD-1/PD-L1 signaling pathway in cancer pathogenesis and treatment: a systematic review;Journal of Cancer Metastasis and Treatment;2024-05-28

3. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives;Journal of Hematology & Oncology;2024-04-29

4. The TOPK Inhibitor HI-TOPK-032 Enhances CAR T-cell Therapy of Hepatocellular Carcinoma by Upregulating Memory T Cells;Cancer Immunology Research;2024-02-26

5. Chimeric Antigen Receptor T Cell Therapy for Hepatocellular Carcinoma: Where Do We Stand?;International Journal of Molecular Sciences;2024-02-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3